Advertisement
Advertisement
U.S. Markets close in 4 hrs 29 mins
Advertisement
Advertisement
Advertisement
Advertisement

Ocular Therapeutix, Inc. (OCUL)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.3500-0.0500 (-1.47%)
As of 04:00PM EDT. Market open.
Advertisement
Sign in to post a message.
  • D
    DHARA
    Analysts have lowered price target, but maintain their rating..
    Hopefully it improves once company announce positive readout on its pipeline..
  • A
    Andrew
    Only stock in the red in my portfolio today. Unreal
  • C
    Chris
    Any thoughts on the Qtr ..and Rev guidance / Conf call Etc... Overall I was happy with 12.5 Dex Rev considering Jan was hindered significantly by COVID .
  • A
    AARON
    Insider Purchases - Short Term Profit Analysis
    In this section, we analyze the profitability of every unplanned, open-market insider purchase made by Heier Jeffrey S. in OCUL / Ocular Therapeutix Inc. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.
    The following table shows the most recent open market purchases that were not part of an automatic trading plan.
    Trade Date
    Reported
    Shares
    Reported
    Price
    Adjusted
    Shares
    Adjusted
    Price
    Cost Basis
    Days to
    Max
    Price at
    Max
    Max
    Profit ($)
    Max Return (%)
    2022-05-12
    15,000
    3.0500
    15,000
    3.0500
    45,750
    4
    3.3500
    4,500
    9.84
    2019-03-15
    24,000
    4.1500
    24,000
    4.1500
    99,600
    Bullish
  • A
    Anonymous
    JayHawk down...may day...Mayday
  • A
    AARON
    A 3 day winning streak,. HAvent seen that in like a year and half.
  • D
    DHARA
    Hi, can anyone shed light on gene & cell therapy, how big the market and chance of OCUl being successful reaching their goals, risk factors, etc..?
    Recent PR about pre-clinical activity seems pretty exciting..
    Thanks
  • j
    jaimie
    It’s like rats fleeing a sinking ship

    I am a long term holder with 5 figures, but my faith in the company has been definitely rocked by the complete lack of comment by investor relations on the price drop. Chris Brinzey won’t return my calls either.

    I don’t know what to think anymore. I’m not expecting the company’s presentations this weekend (none of which are more than 5 minutes long ) to move the sp at all.
  • A
    AARON
    SHANGHAI, April 12, 2022 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products, today announced that DEXTENZA has been approved in Macau, China for the treatment of ocular inflammation and pain following ophthalmic surgery. In 2020, AffaMed Therapeutics entered into a licensing agreement with Ocular Therapeutix (NASDAQ: OCUL) for the development and commercialization of DEXTENZA in Greater China, South Korea, and certain ASEAN markets. DEXTENZA is currently approved in the U.S. for the treatment of ocular inflammation and pain following ophthalmic surgery and for the treatment of ocular itching associated with allergic conjunctivitis.
  • A
    Abraham
    (EYEN) MC $60 m --3x Phase 3 Drugs including a Blockbuster with readout in Q2 =1000% UPSIDE
    https://assets.wallstreet-online.de/_media/8763/board/20220328161719-screenshot-2022-03-28-at-16-16-43-powerpoint-pres.png

    ####
  • o
    ottcschmidlap
    Huge seller

    My guess is the big seller is Opeleye. They were selling for the past few months.

    Sacklers could also be selling but I doubt it. They were buyers in the $5 s and $6 s only weeks ago
  • A
    AARON
    Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced multiple scientific presentations at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting being held April 22-26, 2022 in Washington, D.C.
    "We are excited to have such a large presence at this year’s ASCRS which we believe highlights the interest in DEXTENZA® as well as our other ocular surface programs," commented Michael Goldstein, MD, MBA, President, Ophthalmology and Chief Medical Officer of Ocular Therapeutix. "The data we are presenting includes updates on DEXTENZA, which is commercially available to treat inflammation and pain associated ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and OTX-DED for the treatment of dry eye disease. All of the data being presented continue to demonstrate the breadth of our proprietary hydrogel technology and its potential to meet unmet needs in many areas of the ophthalmic space."
  • h
    howard
    Someone has to be accountable. This is why activist exist and play a role. ELT has to be accountable and transparent. Seems like the company has too many leaders and duplicate roles at the top not to mention pay seems high for a company that isn't making money or growing. Too bad as this could be a great win for the market, patients, and shareholders.
  • o
    ottcschmidlap
    Looks like the seller is back

    The volume selloff between 3 pm and 4 pm daily is the telltale sign. Thats been the M O for the past few weeks
  • D
    Dean
    this is a decent company
  • S
    Steven2
    Has Tony or anyone else within OCUL's senior management talked with Wilmer Hale about OCUL's being included on the DoJ's surveillance list for illegal (share price manipulative) shorting. If not, they should. (easy call to contacts, including former W&H colleagues, at DoJ and SEC enforcement. This illegal shorting has been going on systematically ever since Dextenza was first approved by the FDA, but has increased in intensity and deliberate notoriety since the share price reached into the 23s late last year.
    Bullish
  • o
    ottcschmidlap
    Opaleye has to file a 13 f/g in May showing their Q1 holdings

    Management can buy but not till after Q1 earnings are released

    Really sad $6 or $7 bid buys the company now

    Maybe Sawheny comes back into the picture for a buyout
  • b
    babbobubba
    A sincere question... How can this company have $2.15 in cash – twice as much cash as debt – and have a book value of $1.15?
  • a
    arthur
    is it time to maybe start averaging down ? l love to hear some positive feed back .
  • o
    ottcschmidlap
    aren't we entitled to a milestone payment from Affamed for approval in Macau
Advertisement
Advertisement